Rheumatoid arthritis (RA) associates with excess cardiovascular risk and there is a need to assess that risk. However, individual lipid levels may be influenced by disease activity and drug use, whereas lipid ratios may be more robust. A cross-sectional cohort of 400 consecutive patients was used to establish factors that influenced individual lipid levels and lipid ratios in RA, using multiple regression models. A further longitudinal cohort of 550 patients with RA was used to confirm these findings, using generalized estimating equations. Cross-sectionally, higher C-reactive protein (CRP) levels correlated with lower levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol ([HDL-C] P ≤ .015), whereas lipid ratios did not correlate with CRP. The findings were broadly replicated in the longitudinal data. In summary, the effects of inflammation on individual lipid levels may underestimate lipid-associated cardiovascular disease (CVD) risk in RA, thus lipid ratios may be more appropriate for CVD risk stratification in RA.
Symmons D., Turner G., Webb R., et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology ( Oxford). 2002;41(7):793-800.
2.
Van Doornum S. , McColl G., Wicks IPAccelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46(4):862-873.
3.
Pincus T., Callahan LFTaking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986;13(5):841-845.
4.
Situnayake RD , Kitas G.Dyslipidemia and rheumatoid arthritis . Ann Rheum Dis. 1997;56(6):341-342.
5.
Toms TE, Symmons DP, Kitas GDDyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol.2010;8(3):301-326.
6.
Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(9): 1286-1298.
7.
Stevens RJ, Douglas KM, Saeatzis AN, Kitas GDInflammation and atherosclerosis in rheumatoid arthritis. Expert rev mol med. 2005;7(7):1-24.
8.
Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006;65(3):348-353.
9.
van Leuven SI , Franssen R., Kastelein JJ, Levi M., Stroes ES, Tak PPSystemic inflammation as a risk factor for atherothrombosis. Rheumatology ( Oxford ). 2008;47(1):3-7.
10.
Parakevas KI , Mikhailidis DPC-reactive protein (CRP): more than just an innocent bystander? Curr Med Res Opin. 2008 ; 24(1):75-78.
11.
Khouidhunkit W., Memon RA, Feingold KR, Grunfield C.Infection and inflammation induced proatherogenic changes of lipoproteins. J Infect Dis. 2000 ;181(suppl 3):S462-S472.
12.
Choi HK, Seeger JDLipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol . 2005;32(12):2311-2316.
13.
Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis . J Rheumatol. 1999;26(8): 1701-1704.
14.
Peters MJ, Vis M., van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):958-961.
15.
London MG, Muriden KD, Hewitt JVSerum cholesterol in rheumatic diseases. Br Med J . 1963;1(25):1380-1383.
16.
Svenson KL, Lithell H., Hallgren R., Selinus I., Vessby B.Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med. 1987;147(11):1912-1916.
17.
Dursunoglu D., Evrengul H., Polat B., et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int. 2005;25(4):241-245.
18.
Rantapaa-Dahlqvist S., Wallberg-Jonsson S., Dahlen G.Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991;50(6):366-368.
19.
Choy E., Sattar N.Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis.2009;68(4):460-469.
20.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
21.
Department of health: National service framwork for coronary heart disease. London2000.
22.
JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl 5): v1-52.
23.
Toms TE, Panoulas VF, Douglas KMJ, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk. Ann Rheum Dis Epub.2009.
24.
Conroy RM, Pyorala K., Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003.
25.
Sattar N., McInnes IBVascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions . Curr Opin Rheumatol. 2005 ;17(3):286-292.
26.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum . 1988;31(3):315-324.
27.
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PLModified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-48.
28.
Kirwan JR, Reeback JSStanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol . 1986;25(2):206-209.
29.
Matthews DR , Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RCHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
30.
Katz A., Nambi SS, Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7): 2402-2410.
31.
Traynor J., Mactier R., Geddes CC, Fox JGHow to measure renal function in clinical practice. BMJ. 2006;333(7571):733-737.
32.
Panoulas VF , Douglas KM, Stavropoulos-Kalinoglou A., et al. Long-term exposure to medium-dose glucocorticoid therapy assocaites with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008 ;47(1):72-75.
33.
Stavropoulos-kalinglou A., Metsios GS, Panoulas VF, et al. Cigarette smoking associates with body weight and muscle mass of patients with rhuematoid arthritis: a cross sectional, obseravtional study. Arthritis Res Ther. 2008;10(3):R59.
34.
Banks M., Flint J., Bacon PA, Kitas GDRheumatoid arthritis is an independant risk factor for ischaemic heart disease . Arthritis Rheum. 2000;43:s385.
35.
Wallberg-Jonsson S., Ohman ML, Dahlqvist SRCardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997;24(3):445-451.
36.
Ettinger WH , Klinefelter HF, Kwiterovitch POEffect of short-term, low-dose corticosteroids on plasma lipoprotein lipids . Atherosclerosis. 1987;63(2-3):167-172.
37.
Boers M., Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis . Ann Rheum Dis. 2003;62(9):842-845.
38.
Ettinger WH , Goldberg AP, Applebaum-Bowden D., Hazzard WRDyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med. 1987;83(3):503-508.
Rheumatoid arthritis: The managment of rheumatoid arthritis in adults. www.nice.org.uk/guidelines. Accessed 2009.
41.
Beynen ACCan chloroquine be of value in the treatment of hypercholestrolaemia . Artery. 1986;13:340-351.
42.
Munro R., Morrison E., McDonald AG, Hunter JA, Madhok R., Capell HAEffect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56(6):374-377.
43.
Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PACholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990;89(3):322-326.
44.
Wierzbicki AS, Poston R., Ferro A.The lipid and non-lipid effects of statins . Pharmacol Ther. 2003 ;99(1):95-112.
45.
Tziomalos K. , Kakafika AL, Athyros VG, Karagiannis A., Mikhailidis DPThe role of statins in primary and secondary prevention of coronary heart disease in women. Curr Pharm Des.2009;15(10):1054-1062.
46.
Kakafika A. , Athyros VG, Tziomalos K., Karagiannis A., Mikhailidis DPHigh density lipoproein cholesterol and statin trials. Curr Med Chem. 2008;15(22):2265-2270.
47.
McCarey DW, McInnes IB, Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double blind, randomised placebo-controlled trial. Lancet. 2004;363(9426): 2015-2021.
